Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.64 |
| ▸ | GCGR | P47871 | 1/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.52 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.52 |
| ▸ | TNKS | O95271 | 3/20 | 0.51 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.51 |
| ▸ | PARP1 | P09874 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.50 |
| ▸ | SCD | O00767 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31063780 | 1.00 | HDAC6 (0.64) | HDAC6GCGRTRPV1NPBWR1TNKS | |
| SCHEMBL9032997 | 0.87 | ALDH1A1 (0.62) | NPBWR1KDM4EALDH1A1HPGDMEN1 | |
| SCHEMBL3335014 | 0.86 | ALDH1A1 (0.61) | NPBWR1TNKSTNKS2KDM4EALDH1A1 | |
| SCHEMBL22955865 | 0.85 | KDM4E (0.50) | HDAC6NPBWR1KDM4EALDH1A1HPGD | |
| SCHEMBL2360806 | 0.84 | CSNK1D (0.51) | HDAC6GCGRTRPV1NPBWR1TNKS | |
| SCHEMBL31027896 | 0.84 | HDAC6 (0.66) | HDAC6TRPV1NPBWR1TNKSTNKS2 | |
| SCHEMBL21705321 | 0.84 | HDAC6 (0.66) | HDAC6TRPV1NPBWR1TNKSTNKS2 | |
| SCHEMBL22452444 | 0.82 | HDAC6 (0.64) | HDAC6TRPV1NPBWR1TNKSTNKS2 | |
| SCHEMBL21705325 | 0.82 | HDAC6 (0.64) | HDAC6TRPV1NPBWR1TNKSTNKS2 | |
| SCHEMBL22452314 | 0.82 | HDAC6 (0.64) | HDAC6TRPV1NPBWR1TNKSTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300877-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-09-30 | — | — | US | disclosed |
| US-11111217-B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210061769-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-03-04 | — | — | US | disclosed |
| US-10851066-B2 | 2-arylbenzimidazoles as PPARGC1A activators for treating neurodegenerative diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200299244-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-09-24 | — | — | US | disclosed |
| WO-2020033359-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299244-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | PPARG, PPARA, PPARD | HDAC6 101/4885GCGR 533/4885TRPV1 1245/4885 |
| US-20210300877-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | PPARG, PPARA, PPARD | HDAC6 91/4885GCGR 1822/4885TRPV1 2380/4885 |
| US-20210061769-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | PPARG, PPARA, PPARD | HDAC6 107/4885GCGR 598/4885TRPV1 1157/4885 |
| US-11111217-B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | PPARG, PPARA, PPARD | HDAC6 107/4885GCGR 598/4885TRPV1 1157/4885 |
| US-10851066-B2 | 2-arylbenzimidazoles as PPARGC1A activators for treating neurodegenerative diseases | PPARG, PPARA, PPARD | HDAC6 101/4885GCGR 533/4885TRPV1 1245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.